Q-Line Biotech Limited

Variance Analysis for the FY 2024-25

<table><thead><tr><th>Sr. No.</th><th>Ratio</th><th>Variance</th><th>Reason for Variance Above 25%</th></tr></thead><tbody><tr><td>1</td><td>Trade Payable Turnover Ratio</td><td>-20.8%</td><td>Due to decrease in Trade payables outstanding and increase in Purchases during the year</td></tr><tr><td>2</td><td>Net Capital Turnover Ratio</td><td>35.3%</td><td>Sales increased more than 51% compared to Previous year with moderate increase in working Capital</td></tr><tr><td>3</td><td>Net Profit Ratio (%)</td><td>-47.0%</td><td>Due to Increase in decrease in profit due to exit from Investment during the year as compare to P.Y</td></tr><tr><td>4</td><td>Debt Equity Ratio (No of Times)</td><td>45.0%</td><td>Due to Increase in Long Term Debts during the Financial year</td></tr></tbody></table>

## Annexure â€“ AC

### Other Notes-

1. The title deeds of all immovable properties are held in the name of the Company. Accordingly, there are no Immovable Properties which were not held in name of the Company as on 31st March, 2025.

2. During the year FY 2023-24, the company acquired 63.40% equity interest in IQ-Line Private Limited on 22nd July, 2023 and disposed of the entire interest & control on 28th March 2024.

The investment was made with the intention of disposal in the near term, and control was considered temporary in nature. Accordingly, the subsidiary has not been consolidated as per Paragraph 11(b) of AS 21.

### 3. Losses of Subsidiaries Exceeding Minority Interest:

In accordance with AS 21, the losses attributable to minority shareholders in certain subsidiaries have exceeded their share in the equity of those subsidiaries. Such excess losses have been absorbed by the parent company, as the minority shareholders do not have a binding obligation to make good these losses. Accordingly, the minority interest in those subsidiaries is presented at NIL in the consolidated financial statements. Disclosure with regard such losses absorbed by parent company is listed below

<table><thead><tr><th rowspan="2">Particulars</th><th colspan="3">For the Year ended on</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td>Q-Line Innovation Private Ltd</td><td>1.36</td><td>NA</td><td>NA</td></tr><tr><td>Q-Line Nutraceuticals Private Limited</td><td>50.74</td><td>12.41</td><td>NA</td></tr></tbody></table>

### 4. Non-Controlling Interest (Minority Interest)

The minority interest in Q-Line Innovation Private Ltd and Q-Line Nutraceuticals Private Limited is restricted to NIL as the subsidiary has accumulated losses exceeding its net worth. The share of losses attributable to minority interest has been adjusted against the parent company's share in accordance with AS 21

#### Minortiy Interest- Q-Line Innovation Private Ltd

<table><thead><tr><th rowspan="2">Particulars</th><th colspan="3">For the Year ended on</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td>Opening Balances</td><td>-</td><td>-</td><td>N.A</td></tr><tr><td>Add:- Share of Profit(Loss) during the period/year</td><td>-</td><td>-</td><td>N.A</td></tr><tr><td><strong>Closing Balance</strong></td><td>-</td><td>-</td><td>N.A</td></tr><tr><td>Q-Line Innovation Private Limited Share acquired on 07th March 2025</td><td></td><td></td><td></td></tr></tbody></table>

#### Minortiy Interest-Q-Line Nutraceuticals Private Limited

<table><thead><tr><th rowspan="2">Particulars</th><th colspan="3">For the Year ended on</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td>Opening Balances</td><td>N.A</td><td>-</td><td>N.A</td></tr><tr><td>Add:- Share of Profit(Loss) during the period/year</td><td>N.A</td><td>-</td><td>N.A</td></tr><tr><td><strong>Closing Balance</strong></td><td>N.A</td><td>-</td><td>N.A</td></tr><tr><td>Q-Line Nutraceuticals Private Limited shares sold on 24th March, 2025.</td><td></td><td></td><td></td></tr></tbody></table>

234